On Monday October 5, a scientific conference on HIV began in Glasgow, Scotland. Among the first presentations, a study showed that two-thirds of people living with HIV would like to switch to long-term injectable treatment. This study, published by aidsmap, took the form of online questionnaires offered in four European countries (France, Germany, Italy and the United Kingdom). The efficacy of the dual therapy combining the antiretrovirals cabotegravir + rilpivirine in its injectable and prolonged-release form (one injection every two months) was demonstrated in the Flair (people who have never taken anti-HIV treatments) and ATLAS trials (people who have already taken anti-HIV treatments).
The questionnaire was conducted under the aegis of the pharmaceutical company ViiV Healthcare, which manufactures the cabotegravir + rilpivirine dual therapy in its injectable form, which could have suggested a bias due to a form of conflict of interest, but the same questionnaire was was conducted independently in Italy with an even higher interest rate for injectable treatments, ie 89% of respondents. Of the 688 people living with HIV who responded to the ViiV Healthcare questionnaire, a third were female, just under a third were over 50, and 89% had an undetectable viral load. Of the total number of respondents, 66% were interested in long-term injectable treatment and this rate increased in certain sub-categories. Thus among those who were afraid of missing a treatment or who felt this take as a daily reminder of living with HIV, 79% were interested. Among those who feared that their HIV status would be revealed because of their treatment, the percentage rose to 88%. Finally, among people who had side effects or co-morbidities, the rate rose to 100%. Respondents also indicated what would be the benefits of switching to long-term injectable treatment. The first criterion was the fact of being able to travel more easily without having to carry a treatment in tablets (56%), then came the fact of reducing the taking of medication (53%) then the fact of reducing the risk of missing a dose ( 51%). Among the brakes expressed by respondents on a possible switch to injectable treatment, there was pain due to the injection itself (35%), the fear of not giving the injection in the right timeframe. time (33%) and the fear of not having time to visit a hospital every two months (32%). These results show a real interest of people living with HIV for this new method of administering antiretrovirals which could make their daily lives easier and for some make life with HIV “lighter”. Almost 25 years after the arrival of the first triple therapies, it is another step towards a better quality of life for some people living with HIV, in connection with Tasp and therapeutic relief.
Références : Akinwunmi B et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and physicians in Western Europe. HIV Glasgow 2020, abstract P014. Celesia M et al. Long-acting treatments: people’s expectations and attending physicians’ preparedness. Are we ready to manage it? HIV Glasgow 2020, abstract P015.